Public Trust Tracker Search

INV-077 · Money & ethics · Conflicts of interest

Health task force appointees allowed to keep drug stocks under ethics waivers

Stage 1 of 5: Reported · News reporting only · Last development 5 Nov 2026

Four of the eight people Health Secretary Robert F. Kennedy Jr. appointed in September 2026 to the U.S. Preventive Services Task Force received conflict-of-interest waivers to serve while owning stock in companies affected by the panel's recommendations, including Eli Lilly and Johnson & Johnson, according to the waivers, which The New York Times obtained through a public records request. In the waivers, AHRQ Director Roger Klein wrote that each member, as one of 16, has "no power to render a final decision on behalf of the United States." Before 2025, such financial conflicts were not considered acceptable on the panel, according to former members and federal officials quoted by the Times.

The waivers are official records but were reported by The New York Times; they have not been published by HHS. The waivers require members to consider recusal on topics that affect their holdings. It is not known whether the holdings are in portfolios managed by third parties. No inquiry by an inspector general, ethics office or Congress has been reported. Being listed is not a finding of wrongdoing.

People
Robert F. Kennedy Jr., Roger D. Klein, Patrick K. Hunter, Ronald P. Karlsberg, Venkatesh L. Murthy, Dennis W. Wulfeck
Agencies
HHS (AHRQ)
Reviewed by
None yet

Timeline

  1. The New York Times reports that four of them, Drs. Patrick Hunter, Ronald Karlsberg, Venkatesh Murthy and Dennis Wulfeck, received AHRQ waivers to serve while owning drug-company stocks, including Eli Lilly, Johnson & Johnson, Merck, Pfizer and Novo Nordisk; according to the waivers, the companies make up no more than 15 to 45 percent of each member's portfolio. [1]

  2. Kennedy appoints eight new members to the U.S. Preventive Services Task Force. [1]

Responses

  • HHS spokeswoman Emily Hilliard: Said a Supreme Court ruling made task force members "special government employees"; "Federal law provides that a waiver issued in accordance with the legal standard is an appropriate remedy for a conflict of interest." AHRQ is updating its procedures. [1]
  • Dr. Dennis Wulfeck: Declined to comment; the other three members did not respond (NYT). [1]

Sources

  1. The New York Times, 5 Nov 2026
  2. Newser, Nov 2026

Cite this case

Public Trust Tracker. "Health task force appointees allowed to keep drug stocks under ethics waivers" (INV-077). Last updated 5 Nov 2026. https://publictrusttracker.org/case/inv-077-health-task-force-appointees-allowed-to-keep-drug-stocks/

Suggest a fact check